Two de novo designs against flat, previously undruggable interfaces. Each from a single design round and confirmed in live cells.
A single round of AI-generated de novo peptides against the CDC20 D-box degron interface more than doubled the cell-death response of Apcin, a known small-molecule CDC20 inhibitor, in HeLa cells.
A ProxAI minibinder selectively intercepts an undruggable kinase-effector interface in immune cells, leaving the target's remaining functions intact. No natural template, one design round, in under three months.
In collaboration with an academic partner laboratory, we are evaluating 6,000 de novo bioPROTAC variants against two undisclosed, functionally linked intracellular targets in a single pooled lentiviral CRISPR screen. Targets and biological context withheld under NDA.
Thirty minutes, your target, no confidential information needed. You leave with the wall your target is up against, the route we would take, and the assays that would prove it.
Prefer to write? Send us your target instead.
